- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02913612
Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) (TIM01)
March 10, 2024 updated by: Kanecia Obie Zimmerman
Efficacy, Safety, and Pharmacokinetics of Timolol in Infants With Infantile Hemangioma (IH)
The purpose of this study is to assess the safety and efficacy of Timolol 0.25% and 0.5% doses.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Primary: Describe the efficacy of 0.25% and 0.5% topical timolol maleate Gel-forming solution (GFS) as assessed through Infantile Hemangioma (IH) changes in volume.
Secondary: Describe the safety of topical timolol maleate GFS for treatment of IH.
Study Type
Interventional
Enrollment (Actual)
105
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Ann and Robert H. Lurie Children's Hospital of Chicago
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Health
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Boston Children's Hospital
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Dartmouth-Hitchcock Medical Center
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadephia
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas Medical School at Houston
-
Longview, Texas, United States, 75605
- DCOL Center for Clinical Research
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College of Wisconsin
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 2 months (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria
- Documented informed consent from legal guardian
- 0-84 days postnatal age at time of first study dose or when enrolled into the non-intervention cohort.
Clinical diagnosis of superficial cutaneous or mucosal infantile hemangioma (must include all of the following):
- Superficial lesion in the dermis
- Thin <2 mm in thickness
- Small >=5 cm at its longest dimension and <=10cm2
- Involves skin or keratinized mucosa
Exclusion Criteria
- History of previous treatment with any pharmacologic or laser therapy for IH
- Ongoing therapy with an oral beta blocker or oral corticosteroid (e.g., cardiac arrhythmia, adrenal insufficiency, upper airway obstruction, tetralogy of fallot (TOF), hypertension, reactive airways disease)
- IH that requires systemic therapy (defined by dynamic complication scale >3)
- IH of the non-keratinized mucosa
- Infants with more than one hemangioma that requires therapy
- Hemodynamically significant cardiovascular disease, as determined by the investigator
- Known allergy to beta blockers or vehicle
- Heart rate <100 beats per minute at screening visit
- Known prenatal or postnatal diagnosis of 2nd/3rd degree atrioventricular block
- History of Reactive Airways Disease (RAD)
- Any condition which would make the participant, in the opinion of the investigator unsuitable for the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 0.25% Timolol Treatment
Subjects assigned to this arm will be randomized to 0.25% timolol for 180 days.
If during the 180 days the subject is considered a treatment failure, the subject will be unblinded.
If the subject is on 0.25% timolol they will be changed to 0.5% timolol.
|
50:50 Randomized 0.25% Timolol Maleate Gel Forming Solution
|
Experimental: 0.5% Timolol Treatment
Subjects assigned to this arm will be randomized to 0.5% timolol for 180 days.
If during the 180 days the subject is considered a treatment failure, the subject will be unblinded.
If the subject is on 0.5% timolol the treating physician will decide to either continue 0.5% timolol or withdraw the subject and begin an alternative treatment.
|
50:50 Randomized 0.5% Timolol Maleate Gel Forming Solution
|
No Intervention: Non-Intervention Group
Subjects assigned to this group will not receive treatment.
The subject will only be photographed on the same schedule as the intervention group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Partial Response of Hemangioma Volume as Measured by VAS (Visual Analog Scale) Within Each Treatment Arm and Compared With Untreated Controls
Time Frame: 180 days
|
The VAS-volume is a 100 mm scale used to independently grade hemangioma volume.
-100 indicates hemangioma has doubled in size, 0 indicates no change, and +100 indicates complete shrinkage.
Partial response is defined as >20% and up to 80% reduction in volumetric size of hemangioma.
|
180 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Partial Response in Hemangioma Color as Measured by VAS (Visual Analog Scale) Within Each Treatment Arm and Compared With Untreated Controls
Time Frame: 180 days
|
The VAS-color is a 100 mm scale used to independently grade hemangioma color.
-100 indicates hemangioma is twice as intense, 0 indicates no change, and +100 indicates complete resolution.
Partial response is defined as >30% and up to 80% reduction in color of hemangioma.
|
180 days
|
Number of Participants With Partial Response of Hemangioma Volume as Measured by VAS (Visual Analog Scale) Within Each Treatment Arm
Time Frame: 180 days
|
The VAS-volume is a 100 mm scale used to independently grade hemangioma volume.
-100 indicates hemangioma has doubled in size, 0 indicates no change, and +100 indicates complete shrinkage.
Partial response is defined as >20% and up to 80% reduction in volumetric size of hemangioma.
|
180 days
|
Comparison of Partial Response of Hemangioma Color From Baseline to 180 Days, Within Each Treatment Arm
Time Frame: 180 days
|
Comparison of partial response of hemangioma color (partial response or greater as assessed by VAS-color) between the two treatment arms.
Partial response: >30% and up to 80% reduction in color of hemangioma.
|
180 days
|
Change in Hemangioma Dynamic Complication Scale (HDCS)
Time Frame: baseline, day 180
|
Absolute change in hemangioma dynamic complication scale from Day 0 to end of study within each treatment arm.
The HDCS provides a 6-point severity grading system for 12 individual hemangioma-related complications (grade 0 represents absent to minimal; grade 5 = most severe).
The total score ranges from 0-60.
|
baseline, day 180
|
Number of Participants Who Reach Partial Response, Assessed by Hemangioma Color
Time Frame: 180 days
|
Assess time to partial response or greater by VAS-color, comparing baseline to day 30, day 60, day 120 and day 180.
Partial response: >30% and up to 80% reduction in color of hemangioma
|
180 days
|
Number of Serious Adverse Events and Adverse Events of Special Interest in Infants Treated With Topical Timolol Maleate
Time Frame: up to 270 days
|
Serious adverse events and adverse events of special interest from randomization to Day 180 in infants treated with topical timolol maleate (0.25% and 0.5%) GFS for the treatment of infantile hemangioma.
|
up to 270 days
|
Number of Participants Who Reach Partial Response, Assessed by Volume
Time Frame: 30 days, 60 days, 120 days, 180 days
|
Assess time to partial response or greater by VAS-volume, comparing baseline to day 30, day 60, day 120 and day 180.
Partial response: >20% and up to 80% reduction in volumetric size of hemangioma
|
30 days, 60 days, 120 days, 180 days
|
Change in Hemangioma Quality of Life (IH-QoL) Assessment for Infants
Time Frame: baseline, day 180
|
Absolute change in IH-QoL score scale from Day 0 to end of study within each treatment arm.
The IH-QoL score scale consists of 4 domains (physical symptom of patient, social functioning of patient, social and psychological functioning of caregiver, and emotional functioning of caregiver) and 29 items, with each item scored on a Likert scale : 0 = never a problem, 1 = almost never a problem, 2 = sometimes a problem, 3 = often a problem and 4 = almost always a problem).
The total range is 0-116; the higher the total number indicates a worse outcome.
|
baseline, day 180
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (PK) Analysis Measuring Maximum Concentration of Timolol in Plasma Specimen
Time Frame: Up to 12 hours
|
The PK blood samples will be 1.0 ml each and collected between the following timeframes after application of Timolol: within 2 hours, 2-4 hours, 5-7 hours, 8-10 hours or 11-12 hours.
|
Up to 12 hours
|
Pharmacokinetics (PK) Analysis Measuring Area Under the Curve of Timolol in Plasma Specimen
Time Frame: Up to 12 hours
|
The PK blood samples will be 1.0 ml each and collected between the following timeframes after application of Timolol: within 2 hours, 2-4 hours, 5-7 hours, 8-10 hours or 11-12 hours.
|
Up to 12 hours
|
Pharmacokinetics (PK) Analysis Measuring Volume of Distribution of Timolol in Plasma Specimen
Time Frame: Up to 12 hours
|
The PK blood samples will be 1.0 ml each and collected between the following timeframes after application of Timolol: within 2 hours, 2-4 hours, 5-7 hours, 8-10 hours or 11-12 hours.
|
Up to 12 hours
|
Pharmacokinetics (PK) Analysis Measuring Clearance of Timolol in Plasma Specimen
Time Frame: Up to 12 hours
|
The PK blood samples will be 1.0 ml each and collected between the following timeframes after application of Timolol: within 2 hours, 2-4 hours, 5-7 hours, 8-10 hours or 11-12 hours.
|
Up to 12 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Kanecia Zimmerman, MD, MHS, Duke Clinical Research Institute
- Study Chair: Kristin Holland, MD, Medical College of Wisconsin
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 5, 2017
Primary Completion (Actual)
October 20, 2020
Study Completion (Actual)
October 20, 2020
Study Registration Dates
First Submitted
August 12, 2016
First Submitted That Met QC Criteria
September 21, 2016
First Posted (Estimated)
September 26, 2016
Study Record Updates
Last Update Posted (Actual)
March 12, 2024
Last Update Submitted That Met QC Criteria
March 10, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Congenital Abnormalities
- Skin Abnormalities
- Neoplasms, Vascular Tissue
- Hemangioma, Capillary
- Port-Wine Stain
- Hemangioma
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Enzyme Inhibitors
- Timolol
- Pharmaceutical Solutions
- Maleic acid
Other Study ID Numbers
- Pro00068212
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infantile Hemangioma
-
King Edward Medical UniversityCompletedComparison of Efficacy of Sclerotherapy in Infantile HemangiomaPakistan
-
Qilu Hospital of Shandong UniversityCompletedInfantile Haemangiomas
-
Children's Hospital Medical Center, CincinnatiSociety for Pediatric DermatologyCompleted
-
Zhujiang HospitalUnknownInfantile Hemangioma | Capillary Hemangioma | Capillary Hemangiomas | Hemangioma, Capillary Infantile | Strawberry HemangiomaChina
-
Joyce TengStanford UniversityNot yet recruiting
-
Children's Hospital of PhiladelphiaSociety for Pediatric DermatologyWithdrawn
-
Ain Shams UniversityUnknown
-
The Hospital for Sick ChildrenCompleted
-
Assiut UniversityUnknown
-
Seattle Children's HospitalTerminated
Clinical Trials on 0.25% Timolol Maleate Gel Forming Solution
-
Hopital FochNot yet recruiting
-
Vistakon PharmaceuticalsCompletedOcular Hypertension | Glaucoma, Open AngleUnited States
-
Innovative MedicalUnknownDry Eye SyndromesUnited States
-
Alcon ResearchCompletedOcular Hypertension | Open-angle GlaucomaUnited States
-
Alcon ResearchCompletedOcular Hypertension | Open-Angle GlaucomaUnited States
-
Children's Hospital of PhiladelphiaSociety for Pediatric DermatologyWithdrawn
-
Alcon ResearchCompletedOcular Hypertension | Open-angle Glaucoma
-
Santen Inc.CompletedOcular Hypertension | Open-angle GlaucomaUnited States
-
Alcon ResearchCompletedOcular Hypertension | GlaucomaUnited States
-
Alcon ResearchCompletedOcular Hypertension | Open-angle GlaucomaUnited States